MAVENCLAD® HAS LOW ADMINISTRATION AND MONITORING REQUIREMENTS, WHILE DISEASE CONTROL* CAN BE SUSTAINED FOR UP TO FOUR YEARS1
Lymphocyte monitoring in Years 1-4 with MAVENCLAD®
Click here for a list of contraindications
Additional pre-treatment assessments required at year 1 and year 21
- A baseline cranial MRI scan (usually within 3 months before initiation)
- Screen for HIV, active tuberculosis and hepatitis B and C
- Screen for latent infections, in particular tuberculosis and hepatitis B and C
- Assess for acute infection
- Assess varicella zoster antibody status and vaccinate** antibody-negative patients
- Individual benefit-risk evaluation in patients with prior malignancy
- Rule out pregnancy in women of childbearing potential. Counsel male and female patients on the potential for
serious risk to the foetus and need for effective contraception during treatment and for at least 6 months
after the last dose